Last reviewed · How we verify
Antihypertensive treatment
Antihypertensive treatment is a Small molecule drug developed by Asan Medical Center. It is currently FDA-approved for Hypertension (essential or secondary). Also known as: device-based blood pressure lowering, lifestyle modification.
Antihypertensive treatment lowers blood pressure through one or more mechanisms such as vasodilation, reduced cardiac output, or decreased peripheral vascular resistance.
Antihypertensive treatment lowers blood pressure through one or more mechanisms such as vasodilation, reduced cardiac output, or decreased peripheral vascular resistance. Used for Hypertension (essential or secondary).
At a glance
| Generic name | Antihypertensive treatment |
|---|---|
| Also known as | device-based blood pressure lowering, lifestyle modification |
| Sponsor | Asan Medical Center |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Antihypertensive drugs represent a broad class of medications used to manage hypertension by targeting various physiological pathways. Common mechanisms include inhibition of the renin-angiotensin-aldosterone system (ACE inhibitors, ARBs), beta-adrenergic blockade, calcium channel antagonism, or direct vasodilation. The specific mechanism depends on the particular antihypertensive agent(s) used in the treatment regimen.
Approved indications
- Hypertension (essential or secondary)
Common side effects
- Hypotension
- Dizziness
- Fatigue
- Headache
- Cough (ACE inhibitor-related)
- Hyperkalemia (ACE inhibitor/ARB-related)
Key clinical trials
- Nutritional Ketosis Marfan (NA)
- CENtral Blood Pressure Targeting: A Pragmatic RAndomized Pilot triaL in Advanced Chronic Kidney Disease (NA)
- BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT (NA)
- REnin-guided TherApy With MinEralocorticoid Receptor Antagonists in Primary Aldosteronism - Feasibility Study (NA)
- The GUARDIAN Pilot Trial (NA)
- Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging (PHASE3)
- Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke
- Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antihypertensive treatment CI brief — competitive landscape report
- Antihypertensive treatment updates RSS · CI watch RSS
- Asan Medical Center portfolio CI
Frequently asked questions about Antihypertensive treatment
What is Antihypertensive treatment?
How does Antihypertensive treatment work?
What is Antihypertensive treatment used for?
Who makes Antihypertensive treatment?
Is Antihypertensive treatment also known as anything else?
What development phase is Antihypertensive treatment in?
What are the side effects of Antihypertensive treatment?
Related
- Manufacturer: Asan Medical Center — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension (essential or secondary)
- Also known as: device-based blood pressure lowering, lifestyle modification
- Compare: Antihypertensive treatment vs similar drugs
- Pricing: Antihypertensive treatment cost, discount & access